Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro

Summary

Even though new anticoagulants are being devised with the notion that they do not require regular monitoring, when bleeding occurs, it is important to have an antidote and a reliable test to confirm whether the anticoagulant effects are persisting. We examined the effects of five heparinoids, unfractionated heparin (UFH), tinzaparin, enoxaparin, danaparoid and fondaparinux on the traditional APTT and anti-Xa assays as well as on the calibrated automated thrombogram (CAT). We also studied the ability of protamine sulphate (PS), NovoSeven^®, FEIBA^® and FFP to reverse maximum anticoagulation induced by the different heparinoids. The CAT was the only test to detect the coagulopathy of all the anticoagulants. PS produced complete reversal of UFH, and this could be monitored with all three tests. Tinzaparin can also be completely neutralised in vitro with high doses of PS, but the maximum enoxaparin reversal achieved with PS is only approximately 60%. Fondaparinux does not significantly affect the APTT and PS has no significant effect on its reversal. Only NovoSeven was able to correct the fondaparinux induced CAT abnormalities whilst having no effect on the anti-Xa level. None of the reversal agents was very effective in danaparoid spiked plasma but NovoSeven, at high dose, increased the ETP by 40% and reduced the anti-Xa level from 0.93 to 0.78 IU/ml. We conclude that the CAT is superior to the traditional coagulation tests in that it not only detects the coagulopathy of all the he-parinoids but can be also be used to monitor their reversal.

Keywords

Thrombin generation - APTT - anti-Xa assay - heparinoids - reversal agents

• References

• 1 Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary?. Yes. J Thromb Haemost 2004; 02: 547-550.
• 2 Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary?. No. J Thromb Haemost 2004; 02: 551-554.
• 3 Proctor RR, Rapaport SI. The partial thromboplas-tin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-219.
• 4 Fazel S, Williams WG, Goldman BS. Thinned blood, monkey lungs, and the cold heart. J Card Surg 2004; 19: 275-278.
• 5 Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002; 87: 163-164.
• 6 Al Dieri R, Alban S, Beguin S, et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 02: 1395-1401.
• 7 Al Dieri R, Alban S, Beguin S. et al. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 2006; 04: 83-89.
• 8 Hemker HC, Al Dieri R, Beguin S. Laboratory monitoring of low-molecular-weight heparin therapy--part II. Monitoring LMWH therapy? For the moment a non-question. J Thromb Haemost 2005; 03: 571-573.
• 9 Houbouyan L, Boutiere B, Contant G. et al. Vali-dation protocol of analytical hemostasis systems: measurement of anti-Xa activity of low-molecular-weight heparins. Clin Chem 1996; 42: 1223-1230.
• 10 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. PathophysiolHaemostThromb 2003; 33: 4-15.
• 11 Petros S, Siegemund T, Siegemund A. et al. The effect of different anticoagulants on thrombin generation. Blood Coagul Fibrinolysis 2006; 17: 131-137.
• 12 Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Seminars in hematology 2004; 41 (Suppl. 01) 65-69.
• 13 Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Canadian journal of anaesthesia. J Canadien Anesth 2002; 49: S11-25.
• 14 Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10 (Suppl. 02) 10-16.
• 15 Turecek PL, Varadi K, Gritsch H. et al. FEIBA: mode of action. Haemophilia 2004; 10 (Suppl. 02) 3-9.
• 16 Maddineni J, Hoppensteadt DA, Cornelli U. et al. Relative neutralization of the biological actions of sul-faminoheparosans (K5 derivatives) and heparins by protamine sulfate. ClinApplThromb Hemost 2007; 13: 52-64.
• 17 Baglin T, Barrowcliffe TW, Cohen A. et al. Guidelines on the use and monitoring of heparin. Br J Haema-tol 2006; 133: 19-34.
• 18 Crowther MA, Berry LR, Monagle PT. et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116: 178-186.
• 19 Gerotziafas GT, Depasse F, Chakroun T. et al. Rec-ombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004; 91: 531-537.
• 20 Perzborn E, Strassburger J, Wilmen A. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 03: 514-521.
• 21 Hoffman M, Monroe 3rd DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
• 22 Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109: 1-11.
• 23 Smogorzewska A, Brandt JT, Chandler WL. et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006; 130: 1605-1611.
• 24 Kitchen S, Jennings I, Woods TA. et al. Wide variability in the sensitivity ofAPTT reagents for monitoring of heparin dosage. J Clin Pathol 1996; 49: 10-14.
• 25 Kitchen S, Iampietro R, Woolley AM. et al. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82: 1289-1293.